Compare Prologis Inc (PLD) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs ResMed Inc. — how do they compare? Prologis Inc trades at $129.49 (market cap $122.87B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: Prologis Inc is far larger — about 3.9× ResMed Inc.'s market cap, and Prologis Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and ResMed Inc. for 51 Days on average.
| PLD | RMD | |
|---|---|---|
Market Cap | $122.87B | $31.89B |
Volume | 4,222,957 | 618,314 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $277.88 |
52-Week Low | $111.23 | $182.82 |
Typical Hold Time | 102 Days | 51 Days |
Enterprise Value | $157.61B | $31.24B |
Dividend Yield | 3.31% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLD trades at $129.49, up 1.72% today, with a bearish technical signal from moving averages but strong fundamentals including a 45.79% net income margin and three consecutive quarterly earnings beats. The stock is supported by robust leasing activity and data center growth, as highlighted in recent CFO commentary (Defense World, 2026-09-21).
The outlook is positive with a consensus price target of $155.15 (59.52% buy ratings), but risks include rising debt-to-asset ratio (37.2% in 2025) and market volatility. Upside is driven by warehouse demand and data center expansion, while macroeconomic headwinds pose challenges.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
